Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Otsuka, Lundbeck to collaborate on up to five CNS candidates

Executive Summary

In a long-term alliance, Otsuka Pharmaceutical Co. Ltd. (the pharmaceutical division of Otsuka Holdings Co. Ltd.) and H. Lundbeck AS have agreed to trade licenses to their CNS candidates. Initially Lundbeck receives co-development and co-promotion rights to Otsuka’s Phase III compounds aripiprazole depot and OPC34712 in North and Latin America, Europe, Australia, and all other territories except Asia, Turkey, and Egypt (where Otsuka retains rights). For up to an additional three of Lundbeck’s early-stage undisclosed psychiatric disorder (including schizophrenia) agents, Otsuka has the option to co-develop and co-promote after Phase IIb is complete.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Marketing
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies